NASDAQ: IMCCIM Cannabis Corp Stock
$2.66+0.09 (+3.5%)
Updated Aug 14, 2025
IMCC Price
$2.66
Fair Value Price
N/A
Market Cap
$10.76M
52 Week Low
$1.29
52 Week High
$7.12
P/E
N/A
P/B
4.19x
P/S
0.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$38.26M
Earnings
-$823.36k
Gross Margin
24.2%
Operating Margin
9.5%
Profit Margin
-2.2%
Debt to Equity
10.51
Operating Cash Flow
$2M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMCC Overview
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMCC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
IMCC
Ranked#38 of 58
Ranked#38 of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $30.57 | A | |
| $9.39 | A | |
| $23.17 | A |
Be the first to know about important IMCC news, forecast changes, insider trades & much more!
IMCC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMCC is poor value based on its book value relative to its share price (4.19x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.24x)
P/B vs Industry Valuation
IMCC's Earnings (EBIT) of $3.63M are insufficient to safely cover interest payments on company debt ($11.42M)
Interest Coverage Financials
IMCC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more IMCC due diligence checks available for Premium users.
Valuation
IMCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-10.62x
Market
36.29x
IMCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.19x
Industry
2.24x
IMCC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMCC's financial health
Profit margin
Revenue
$9.3M
Net Income
-$141.6k
Profit Margin
-1.5%
IMCC's Earnings (EBIT) of $3.63M... subscribe to Premium to read more.
Interest Coverage Financials
IMCC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.0M
Liabilities
$27.0M
Debt to equity
10.51
IMCC's short-term liabilities ($25.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMCC's short-term assets ($18.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$346.0k
Investing
$13.9k
Financing
$32.8k
IMCC's operating cash flow ($1.86M)... subscribe to Premium to read more.
Debt Coverage Financials
IMCC vs Pharmaceutical Stocks
IM Cannabis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.